Navigation Links
Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Valturna will be approved for sale in any additional markets. Nor can there be any guarantee that Tekturna will be approved for any additional indications or labeling in any market. Neither can there be any guarantee that Valturna, Tekturna or Diovan will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovativ
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
5. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
... cheaper and more efficient is the aim of a ... and Q1 NanoSystems. The university and the company, based ... exclusive licensing of a package of jointly-owned intellectual property ... The agreement covers inventions that enable manufacture of very ...
... GPRO ) announced today that the Company will ... on Wednesday, February 13,2008 at approximately 4:00 p.m. Eastern ... call at 4:30 p.m. ET hosted by Henry L. ... senior,vice president, finance, and chief financial officer., The ...
Cached Biology Technology:Pharmaxis' Aridol Gains First Asian Approval 2Solar energy technology licensed 2Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call 2
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis could ... that act against various bacteria, fungal infections and parasites, ... of Illinois chemists and collaborators. , Led by U. ... the different ways the drug SQ109 attacks the tuberculosis ... other pathogens from yeast to malaria and how ...
(Date:4/17/2014)... 2014. Kessler Foundation has been named awardee of ... Department of Defense Spinal Cord Injury Research Program. ... the randomized, double-blinded, controlled, multi-site clinical trial, which ... strength after spinal cord injury. Dr. Forrest is ... at Kessler Foundation. Two additional sites will participate ...
(Date:4/17/2014)... Down syndrome - or trisomy 21 - is the ... from a chromosomal abnormality where cells of affected individuals ... the human genome). A study conducted by Stylianos Antonarakis ... and Development at the University of Geneva (UNIGE) Faculty ... on how the extra chromosome 21 upsets the equilibrium ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... is fit and well? This is a question which has ... have come up with the answer - using DNA chips. ... UK universities are developing a DNA chip to monitor the ... save the salmon industry thousands and also help conserve dwindling ...
... notable effect on rates of pregnancy and abortion, according to ... emergency contraception is questioned by Professor Anna Glasier, director of ... NHS Trust, Edinburgh, who says it does help some women ... pregnant. , Use of this form of contraception has increased ...
... broccoli was good for you, she just didn't know it ... you and that it contains compounds known to lessen the ... how these compounds work and what their specific targets may ... at the University of Virginia School of Medicine. , ...
Cached Biology News:Special chip provides better picture of salmon health 2Special chip provides better picture of salmon health 3
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... Ciphergens ProteinChip System, Series 4000 incorporates the ... researchers and biologists in biomarker research. The ... fastest route for converting biomarker discoveries to ... The Series 4000 is designed to fit ...
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
Biology Products: